- Across all doses, a significantly greater proportion of patients who remained on upadacitinib showed continuous improvements in skin lesions and pruritus (itch) at week 32 compared to patients re-randomized to placebo[1]
- At week 32, patients who switched from placebo to upadacitinib 30 mg at week 16 showed greater improvements in skin lesions and itch compared to those remaining on placebo[1]
- Results from an additional analysis of a subset of patients receiving upadacitinib 30 mg reported greater improvements in itch and sleep disturbance compared to those receiving placebo at week 16[2]
- Upadacitinib, an investigational oral agent engineered by AbbVie to selectively inhibit JAK1, is being studied as a once-daily therapy in atopic dermatitis and the Phase 3 clinical program was initiated in August 2018[3],[4]
PR Newswire
NORTH CHICAGO, Ill., Sept. 13, 2018
